Evidence map›Paper›PMID 42121898›Full record

ArticleCells2026

Tumor-Infiltrating Natural Killer Cell Characterization in Pancreatic Ductal Adenocarcinoma.

Andreia Maia, Hasti Calá, Eric de Sousa, Joana R Lérias, Carolina M Gorgulho, Patrícia A António, Jéssica Kamiki, Dário Ligeiro, Luis M Borrego, Markus Maeurer and 1 more

Abstract read
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andreia MaiaMolecular and Experimental Pathology Laboratory, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.ORCID 0000-0002-7860-6219
Hasti CaláMolecular and Experimental Pathology Laboratory, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.ORCID 0000-0002-4021-544X
Eric de SousaImmunoSurgery/ImmunoTherapy Laboratory, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.ORCID 0000-0001-6582-7365
Joana R LériasImmunoSurgery/ImmunoTherapy Laboratory, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.ORCID 0000-0002-9874-5259
Carolina M GorgulhoImmunoSurgery/ImmunoTherapy Laboratory, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Patrícia A AntónioImmunoSurgery/ImmunoTherapy Laboratory, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.ORCID 0009-0005-4053-9646
Jéssica KamikiImmunoSurgery/ImmunoTherapy Laboratory, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.ORCID 0009-0005-3900-0934
Dário LigeiroImmunoSurgery/ImmunoTherapy Laboratory, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Luis M BorregoComprehensive Health Research Centre (CHCR), NOVA Medical School, NOVA University of Lisbon, 1099-085 Lisbon, Portugal.ORCID 0000-0003-4708-438X
Markus MaeurerImmunoSurgery/ImmunoTherapy Laboratory, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Mireia Castillo-MartinMolecular and Experimental Pathology Laboratory, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.ORCID 0000-0001-8926-6013

Funding

Fundação para a Ciência e Tecnologia COVID/BD/153545/2024Fundação para a Ciência e Tecnologia SFRH/BD/144965/2019
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has high mortality rates, poor prognosis, and currently limited effective treatments. Natural killer (NK) cells from tumor-infiltrating lymphocytes (TIL) show promise for cancer treatment due to their ability to migrate to the tumor microenvironment (TME) and safe profile. However, expanding functional patient-derived NK cells remains challenging. Here, we cultured, expanded, and characterized TIL-NK cells isolated from central and peripheral tumor regions from PDAC. Ex vivo patient-derived PBMCs and TIL were cultured under IL-2, IL-15, and IL-12 stimulation. Phenotypical and functional NK cell characterization was assessed at the time of surgery and after 12 days of culture evaluating immunophenotype, expansion rate, and activation. A distinct distribution of NK cell infiltration was observed within the TME, with higher NK cell numbers in the periphery of the tumor compared to the central area. Most NK cells displayed a cytotoxic phenotype (CD56

Indexed as

Carcinoma, Pancreatic DuctalKiller Cells, NaturalLymphocytes, Tumor-InfiltratingPancreatic NeoplasmsAgedFemaleHumansLymphocyte ActivationMaleMiddle AgedTumor Microenvironmentadoptive cell therapynatural killer cellsNK-TILpancreatic ductal adenocarcinomasolid tumoursTIL therapytumor-infiltrating lymphocytes

Identifiers

PMID42121898
PMCPMC13162876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.